Latest News

Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC
Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

April 12th 2024

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.

Understanding ADC Mechanism of Action Enhances Personalized Medicine in NSCLC
Understanding ADC Mechanism of Action Enhances Personalized Medicine in NSCLC

April 8th 2024

Multiple Resistance Mechanisms Thwart Efficacy for Third-Generation TKIs in NSCLC
Multiple Resistance Mechanisms Thwart Efficacy for Third-Generation TKIs in NSCLC

April 7th 2024

Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC

April 5th 2024

Neoadjuvant Use of ICB in NSCLC Gains Favor
Neoadjuvant Use of ICB in NSCLC Gains Favor

April 4th 2024

More News